Every 8-K that Elicio Therapeutics, Inc. (ELTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ELTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELTX filings page.
Elicio Therapeutics, Inc. (ELTX) has set November 12, 2026 as the date for its 2026 annual meeting of stockholders. The company will provide the exact time, location and voting matters in its future proxy statement.
Because this meeting date is more than 30 days later than the prior year’s meeting, stockholder proposals for inclusion under Rule 14a-8, as well as director nominations and other business under the company’s bylaws, must be received by the company’s Secretary at its Boston headquarters by September 24, 2026. The same September 24, 2026 deadline applies to notices required under the universal proxy rules for stockholders intending to solicit proxies for their own director nominees.
Elicio Therapeutics, Inc. reported second quarter 2026 results and clinical updates focused on its lead KRAS-targeted immunotherapy ELI-002 7P. For the quarter ended June 30, 2026, net loss was $8.2 million compared with $10.6 million a year earlier, or $0.43 per share versus $0.66. Research and development expense was $6.8 million and general and administrative expense was $3.6 million. Cash and cash equivalents totaled $23.5 million on June 30, 2026, supported by $16.6 million in at-the-market proceeds year-to-date and a subsequent $15.0 million registered direct financing in July 2026; the company expects this cash to fund operations into the first quarter of 2027. Clinically, a Phase 2 AMPLIFY-7P trial in adjuvant pancreatic cancer did not meet its primary endpoint, while Elicio reported multiple complete responses in metastatic KRAS-mutant pancreatic cancer and plans a Phase 1 combination trial in metastatic disease anticipated to start in the fourth quarter of 2026.
Elicio Therapeutics, Inc. entered into a securities purchase agreement for a registered direct offering of 4,380,313 shares of common stock at $3.43 per share, for aggregate gross proceeds of about $15 million before fees and expenses. The offering is being conducted under Elicio’s effective Form S-3 shelf registration statement and is expected to close on or about July 6, 2026, subject to customary conditions.
The company agreed to a 30-day restriction on issuing additional common stock or equivalents after closing. Elicio intends to use net proceeds, together with existing cash and investments, primarily to fund planned Phase 1 development of ELI-002 7P in metastatic pancreatic ductal adenocarcinoma, its broader pipeline and platform, and for working capital and general corporate purposes.
Elicio Therapeutics, Inc. furnished an investor presentation after hosting a virtual key opinion leader event on the path forward for its cancer vaccine candidate ELI-002 7P in metastatic KRAS-mutant pancreatic ductal adenocarcinoma. Clinicians discussed historical data showing complete responses are rare in metastatic pancreatic cancer, even with modern chemotherapy and immunotherapy combinations.
The presentation highlighted three patients previously treated with ELI-002 7P who later received nivolumab-based therapy and achieved complete radiographic, metabolic and biomarker responses, with two maintaining responses for at least nine months. Elicio outlined a planned, funding-dependent Phase 1 study combining ELI-002 7P with checkpoint inhibition and chemotherapy in recurrent and treatment‑naïve metastatic disease to generate early clinical and immune-response signals within 3–6 months of study start.
Elicio Therapeutics, Inc. reported preliminary clinical observations in metastatic mutant KRAS pancreatic cancer after treatment with its investigational immunotherapy ELI-002 7P. Three patients who had progressed on ELI-002 7P in the Phase 2 AMPLIFY-7P study later received nivolumab-based therapy and achieved 100% confirmed complete radiographic and complete metabolic responses, with concurrent normalization of CA19-9 tumor marker levels and persistent mKRAS-specific T cell responses.
The company notes that complete responses in metastatic pancreatic cancer have been reported at roughly 0%–8% in published studies, making these three complete, durable responses in microsatellite stable / mismatch repair proficient patients notable. Elicio plans, subject to funding, to initiate a Phase 1 study of ELI-002 7P combined with standard chemotherapy and an anti–PD-1 inhibitor in first-line metastatic pancreatic ductal adenocarcinoma, and will host a virtual key opinion leader event on June 24, 2026 to further discuss the findings.
Elicio Therapeutics reported detailed results from its randomized Phase 2 AMPLIFY-7P trial of ELI-002 7P in adjuvant mKRAS-driven pancreatic cancer. The study’s primary endpoint of disease-free survival in the intent-to-treat population was not met, but early landmark analyses showed about a 14% absolute DFS benefit during active treatment at 3 and 6 months, with curve separation through 9 months.
Post-hoc analyses highlighted a stronger effect in completely resected R0 patients, where ELI-002 7P achieved a DFS hazard ratio of 0.65 and median DFS of 23.8 months versus 12.8 months for observation. Higher-risk R1 resections were more common in the ELI-002 arm, which the company believes dampened overall results. mKRAS-specific T cell responses strongly correlated with improved DFS, and safety was favorable with no treatment-related discontinuations or deaths. Elicio plans a Phase 3 trial focused on R0 patients with extended dosing and expects current cash to fund operations into the fourth quarter of 2026, while evaluating additional financing and partnering options.
Elicio Therapeutics reported first quarter 2026 results and highlighted progress in its Phase 2 AMPLIFY-7P trial of ELI-002 7P in KRAS-driven pancreatic cancer. The primary disease-free survival analysis is expected mid-year 2026, and fewer disease progressions and deaths than projected have been observed so far.
R&D expenses were $6.8 million versus $7.8 million a year earlier, while G&A expenses rose to $3.8 million from $3.0 million. Net loss was $11.8 million compared to $11.2 million, with net loss per share improving to $0.65 from $0.87.
Cash and cash equivalents were $14.9 million at March 31, 2026, down from $18.6 million at December 31, 2025. The company raised approximately $13.0 million through its at-the-market program in Q1 and early Q2 2026 and now expects its cash runway to extend into Q4 2026, beyond the anticipated AMPLIFY-7P DFS readout.
Elicio Therapeutics, Inc. entered into an at-the-market stock sales program allowing it to issue and sell up to $100.0 million of common stock from time to time through B. Riley Securities, JonesTrading and Ladenburg Thalmann under a new Sales Agreement.
Sales will be made pursuant to an effective Form S-3 shelf registration, with the agents earning a 3.0% commission on gross proceeds. The company is not required to sell any shares and can terminate the arrangement on short notice.
Elicio also terminated its prior Capital on Demand Sales Agreement with JonesTrading, which had allowed sales of up to $40.0 million of common stock, and confirmed there are no termination penalties and no further shares may be sold under that earlier program.
Elicio Therapeutics reported 2025 results and highlighted progress for its lead KRAS-targeted cancer immunotherapy ELI-002 7P. R&D expense fell to $24.9 million from $33.7 million in 2024 as its Phase 2 AMPLIFY-7P trial moved more patients into observation, while G&A rose to $12.8 million from $11.3 million. Net loss narrowed to $39.5 million, or $2.58 per share, from $51.9 million, or $4.25 per share. Cash and cash equivalents were $18.6 million as of December 31, 2025, up from $17.6 million a year earlier, helped by at-the-market equity proceeds of about $4.9 million in Q4 2025 and $6.3 million in Q1 2026 to date.
The company reiterated that its cash plus expected at-the-market proceeds are projected to fund operations into Q3 2026, beyond the anticipated event-driven primary disease-free survival analysis for the Phase 2 AMPLIFY-7P trial in the first half of 2026. Elicio reported fewer disease progressions and deaths than projected to date in this randomized study and plans to seek an End-of-Phase 2 meeting with the FDA, finalize a Phase 3 protocol, and advance ELI-002 7P toward a registrational trial in resected mKRAS pancreatic cancer, while exploring expansion into neoadjuvant, metastatic PDAC and other mKRAS-positive tumors.
Elicio Therapeutics (ELTX) filed an 8-K announcing financial results for the quarter ended September 30, 2025 and providing corporate updates. The company furnished a press release as Exhibit 99.1 with additional details.
The information furnished, including Exhibit 99.1, is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.
Elicio Therapeutics, Inc. (ELTX) filed a Form 8-K reporting a material event and included three exhibits: a press release dated September 17, 2025, a corporate presentation dated September 17, 2025, and the AMPLIFY-7P trial attachment listed as Exhibit 99.2. The filing references T‑cell response metrics related to mKRAS (including T cell response rate, average and median fold change, and thresholds correlating with clinical activity) and notes the inclusion of CD4+ and CD8+ responses as well as responses to seven mKRAS antigens and patient tumor antigens. The document is signed by Robert Connelly, President and Chief Executive Officer.
The filing supplies named exhibits that investors can review for trial details and corporate messaging; the 8-K itself does not disclose additional numerical trial outcomes in the provided excerpt, so readers should consult the attached press release, presentation, and Exhibit 99.2 for complete data.
Elicio Therapeutics reported that follow-up data from its Phase 1 AMPLIFY-201 study of ELI-002 were published in the peer-reviewed journal Nature Medicine. The company issued a press release announcing the publication, which is attached to this report as Exhibit 99.1 and incorporated by reference. The filing identifies the company as a Delaware corporation with common stock trading under the ticker ELTX on The Nasdaq Capital Market. This disclosure is limited to the publication notice and the inclusion of the press release as an exhibit; no financial results, trial outcomes, or operational actions are presented within the report.